

July 02, 2021

National Stock Exchange of India Ltd Listing Department Exchange Plaza, 5th Floor, Plot No: C/1, G - Block, Bandra - Kurla Complex, Bandra (East), Mumbai - 400 051 NSE Symbol: ORCHPHARMA	BSE Limited Corporate Relationship Department 1st floor, New Trading Ring, Rotunda Building, P J Towers, Dalal Street, Fort Mumbai - 400 001 BSE Code: 524372
---	--

Sub: Disclosures under Regulation 7(2) of SEBI (Prohibition of Insider Trading) Regulations, 2015

Dear Sir/Madam

With reference to the captioned subject, Please find enclosed herewith a declaration submitted by M/s. Dhanuka Laboratories Limited, Promoter to the Company under Regulation 7(2) of SEBI (Prohibition of Insider Trading) Regulations, 2015

Kindly take the above on your records.

Thanking you,

Yours faithfully

For **Orchid Pharma Limited**

313, Valluvarcottam
High Road
Nungambakkam
Chennai - 600 034

Nikita K
*
Company Secretary

FORM C
Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015
[Regulation 7 (2) read with Regulation 6 (2)]-continual disclosure

Name of the company : Orchid Pharma Limited

ISIN of the company : INE191A01027

Details of change in holding of Securities of Promoter, Member of the Promoter Group, Designated Person or Director of a listed company and immediate relatives of such persons and other such persons as mentioned in Regulation 6(2)

Name , PAN No., CIN/DIN & address with contact nos.	Category of Person (Promoter/Member of the Promoter group/designated person /Directors/immediate relative to/others etc.,)	Securities held prior to acquisition/disposal		Securities acquired/disposed				Securities held post acquisition/disposal		Date of allotment advice/ acquisition-of shares/ disposal of shares, specify		Date of intimation to company	Mode of acquisition/disposal (On-market/Public/rights /preferential offer/off-market/inter-transfer/ESOP, etc.,)	Exchange on which the trade was executed
		Type of security (For eg.,- Shares,Warrants,Convertible Debentures,r rights-entitlement etc.,)	No. & % of shareholding	Type of security (For eg.,- Shares,Warrants,Convertible Debentures,r rights-entitlement etc.,)	No.	Value	Transaction type (Purchase/sale /Pledge/Revocation/Invocation/others Please specify)	Type of securities (For eg.,- Shares,Warrants,Convertible Debentures- Rights-entitlement etc.,)	No. & % of shareholding	From	To			
1	2	3	4	5	6	7	8	9	10	11	12	13	14	15
M/s Dhanuka Laboratories Limited	Promoter	Equity shares	36719957 equity shares & 89.96	Equity shares	12000022#	11000000000	Pledge	Equity shares	36719957 equity shares & 89.96	30.06.2021	30.06.2021	01.07.2021	Pledge of equity shares	NA
CIN NO.: U24100DL1993PLC052285														
PAN NO: AAACD2877R														
Address : 82, Abhinash Mansion, First Floor, Joshi Road, Karol Bagh, New Delhi-110005														
Contact no: 95609 29417														

In addition to pledge on 12000022 equity shares, Non-disposal undertaking for 8000015 equity shares aggregating to 19.60% of share capital has been made on June 30,2021

Details of trading in derivatives on the securities of the company by Promoter, member of the promoter group, designated person or Director of a listed company and immediate relatives of such persons and other such persons as mentioned in Regulation 6(2)

Trading in derivatives (Specify type of contract , Futures or Options etc.,)						Exchange on which the trade was executed
Type of contract	Contract specifications	Buy		sell		
		Notional value	Number of units (Contracts* lot size)	Notional value	Number of units (Contracts* lot size)	
16	17	18	19	20	21	22
NOT APPLICABLE						

Note: In case of Options, notional value shall be calculated based on Premium plus strike price of options.

For Dhanuka Laboratories Limited

Manish Dhanuka

Manish Dhanuka
Managing Director
Date: 02.07.2021
Place: New Delhi



Note: (i) "Securities" shall have the meaning as defined under regulation 2(1)(i) of SEBI (Prohibition of Insider Trading) Regulations, 2015.
(ii) Value of transaction excludes taxes/brokerage/any other charges